Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 May;37(5):1193–1196. doi: 10.1128/aac.37.5.1193

Effects of probenecid on the pharmacokinetics of allopurinol riboside.

J B Were 1, T A Shapiro 1
PMCID: PMC187932  PMID: 8517715

Abstract

Allopurinol riboside is an experimental agent for the treatment of leishmaniasis and American trypanosomiasis. Previous studies showed that after oral administration, unexpectedly low levels of allopurinol riboside in plasma are attributable to incomplete absorption and rapid renal clearance. In this randomized, crossover evaluation in healthy volunteers, probenecid reduces the renal clearance of allopurinol riboside, extends the half-life of allopurinol riboside in plasma, and triples the levels of allopurinol riboside in plasma.

Full text

PDF
1193

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berens R. L., Marr J. J., Nelson D. J., LaFon S. W. Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochem Pharmacol. 1980 Sep 1;29(17):2397–2398. doi: 10.1016/0006-2952(80)90275-0. [DOI] [PubMed] [Google Scholar]
  2. Boyd M. R., Bacon T. H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother. 1987 Aug;31(8):1238–1242. doi: 10.1128/aac.31.8.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Cunningham R. F., Israili Z. H., Dayton P. G. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981 Mar-Apr;6(2):135–151. doi: 10.2165/00003088-198106020-00004. [DOI] [PubMed] [Google Scholar]
  5. Elion G. B., Kovensky A., Hitchings G. H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966 Jul;15(7):863–880. doi: 10.1016/0006-2952(66)90163-8. [DOI] [PubMed] [Google Scholar]
  6. Elion G. B., Yü T. F., Gutman A. B., Hitchings G. H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968 Jul;45(1):69–77. doi: 10.1016/0002-9343(68)90008-9. [DOI] [PubMed] [Google Scholar]
  7. Kornhauser D. M., Petty B. G., Hendrix C. W., Woods A. S., Nerhood L. J., Bartlett J. G., Lietman P. S. Probenecid and zidovudine metabolism. Lancet. 1989 Aug 26;2(8661):473–475. doi: 10.1016/s0140-6736(89)92087-4. [DOI] [PubMed] [Google Scholar]
  8. Krenitsky T. A., Hall W. W., de Miranda P., Beauchamp L. M., Schaeffer H. J., Whiteman P. D. 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc Natl Acad Sci U S A. 1984 May;81(10):3209–3213. doi: 10.1073/pnas.81.10.3209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Laskin O. L., de Miranda P., King D. H., Page D. A., Longstreth J. A., Rocco L., Lietman P. S. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother. 1982 May;21(5):804–807. doi: 10.1128/aac.21.5.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Marr J. J., Berens R. L. Antileishmanial effect of allopurinol. II. Relationship of adenine metabolism in Leishmania species to the action of allopurinol. J Infect Dis. 1977 Dec;136(6):724–732. doi: 10.1093/infdis/136.6.724. [DOI] [PubMed] [Google Scholar]
  11. Marr J. J., Berens R. L., Nelson D. J. Antitrypanosomal effect of allopurinol: conversion in vivo to aminopyrazolopyrimidine nucleotides by Trypanosoma curzi. Science. 1978 Sep 15;201(4360):1018–1020. doi: 10.1126/science.356267. [DOI] [PubMed] [Google Scholar]
  12. Nelson D. J., Bugge C. J., Elion G. B., Berens R. L., Marr J. J. Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani. Allopurinol, oxipurinol, and 4-aminopyrazolo(3,4-d)pyrimidine. J Biol Chem. 1979 May 25;254(10):3959–3964. [PubMed] [Google Scholar]
  13. Nelson D. J., LaFon S. W., Tuttle J. V., Miller W. H., Miller R. L., Krenitsky T. A., Elion G. B., Berens R. L., Marr J. J. Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J Biol Chem. 1979 Nov 25;254(22):11544–11549. [PubMed] [Google Scholar]
  14. Petty B. G., Whitley R. J., Liao S., Krasny H. C., Rocco L. E., Davis L. G., Lietman P. S. Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. Antimicrob Agents Chemother. 1987 Sep;31(9):1317–1322. doi: 10.1128/aac.31.9.1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Saenz R. E., Paz H. M., Johnson C. M., Marr J. J., Nelson D. J., Pattishall K. H., Rogers M. D. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis. 1989 Jul;160(1):153–158. doi: 10.1093/infdis/160.1.153. [DOI] [PubMed] [Google Scholar]
  16. Shapiro T. A., Were J. B., Danso K., Nelson D. J., Desjardins R. E., Pamplin C. L., 3rd Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther. 1991 May;49(5):506–514. doi: 10.1038/clpt.1991.61. [DOI] [PubMed] [Google Scholar]
  17. Simmonds H. A. Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol. Clin Chim Acta. 1969 Feb;23(2):353–364. doi: 10.1016/0009-8981(69)90052-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES